Baseline Characteristics of Patients
| Characteristic | Value (n = 75) | |
| Women (n) | 32 (42.7%) | |
| Median age (y) | 64.0 (range, 46.0–83.0) | |
| Median BMI (kg/m2) | 23.4 (range, 15.8–30.0) | |
| ECOG performance-status score (n) | ||
| 0/1 to 2 | 20 (26.7%)/55 (73.3%) | |
| Primary tumor site (n) | ||
| Gallbladder cancer | 28 (37.3%) | |
| IHCC | 22 (29.3%) | |
| EHCC | 19 (25.3%) | |
| AoV cancer | 6 (8.0%) | |
| Pathologic differentiation (n) | ||
| WD/MD/PD | 3 (4.0%)/38 (50.7%)/12 (16.0%) | |
| HER 2 immunohistochemistry (n) | ||
| Negative to 1+ | 33 (44.0%) | |
| 2+ to 3+ | 10 (13.3%) | |
| HER 2 FISH (n) | ||
| Negative/positive | 5 (6.7%)/3 (4.0%) | |
| c-MET cytoplasm immunohistochemistry (n) | ||
| Negative to 1+ | 36 (48.0%) | |
| 2+ to 3+ | 7 (9.3%) | |
| c-MET membrane immunohistochemistry (n) | ||
| Negative to 1+ | 16 (21.3%) | |
| 2+ to 3+ | 27 (36.0%) | |
| c-Myc | ||
| Negative/positive | 28 (37.3%)/12 (16.0%) | |
| Median CEA (ng/mL) | 2.6 (range, 0.5–182.9) | |
| Median CA 19-9 (U/mL) | 133 (range, 2.0–36,000.0) | |
| Median WBC (μL) | 6,300 (range, 2,890–16,330) | |
| Median total bilirubin (mg/dL) | 0.6 (range, 0.3–3.3) | |
| Median albumin (mg/dL) | 3.9 (range, 3.3–4.7) | |
| Curative/palliative operation (n) | 40 (78.4%)/11 (21.6%) | |
| Unresectable/recurrent disease (n) | 35 (46.7%)/40 (53.3%) | |
| Best response (n) | ||
| PR/SD/PD | 12 (16.7%)/45 (62.5%)/15 (20.8%) | |
| Median follow-up duration (mo) | 6.8 (1.0–27.2) | |
| Median PFS (mo) | 5.6 (95% CI, 4.4–6.8) | |
| Median OS (mo) | 13.2 (95% CI, 7.1–19.3) |
BMI = body mass index; ECOG = Eastern Cooperative Oncology Group; WD = well differentiated; MD = moderately differentiated; PD = poorly differentiated; HER 2 = human epidermal growth factor receptor 2; FISH = fluorescent in situ hybridization; CEA = carcinoembryonic antigen; CA 19-9 = carbohydrate antigen 19-9; WBC = white blood cell; CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease.